Agilon Health (NYSE:AGL) Price Target Raised to $85.00 at JPMorgan Chase & Co.

Agilon Health (NYSE:AGL) had its price target lifted by JPMorgan Chase & Co. from $31.00 to $85.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential downside of 11.11% from the company’s current price.

A number of other equities research analysts also recently weighed in on AGL. Wall Street Zen raised Agilon Health from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings downgraded Agilon Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 27th. Barclays set a $111.00 target price on Agilon Health and gave the stock an “equal weight” rating in a research report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft raised Agilon Health from a “hold” rating to a “buy” rating and boosted their price target for the company from $33.00 to $49.00 in a research note on Thursday, May 7th. Finally, Robert W. Baird set a $116.00 price target on Agilon Health in a research report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Agilon Health presently has an average rating of “Hold” and a consensus price target of $97.70.

Agilon Health Price Performance

Shares of Agilon Health stock traded down $0.95 during trading on Monday, hitting $95.63. 12,212 shares of the company’s stock traded hands, compared to its average volume of 353,263. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.08 and a quick ratio of 1.08. The firm’s fifty day moving average price is $105.84 and its 200 day moving average price is $61.17. Agilon Health has a twelve month low of $7.48 and a twelve month high of $133.04. The company has a market cap of $1.61 billion, a PE ratio of -6.70 and a beta of 3.01.

Agilon Health (NYSE:AGL) last posted its earnings results on Wednesday, August 5th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.90. Agilon Health had a negative net margin of 3.92% and a negative return on equity of 119.38%. The business had revenue of $1.49 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Analysts forecast that Agilon Health will post -2.95 earnings per share for the current year.

Institutional Investors Weigh In On Agilon Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. LPL Financial LLC increased its stake in shares of Agilon Health by 213.4% in the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock valued at $30,000 after acquiring an additional 30,000 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in Agilon Health during the 3rd quarter worth approximately $34,000. Merit Financial Group LLC bought a new position in Agilon Health during the 4th quarter worth approximately $35,000. Focus Partners Advisor Solutions LLC acquired a new position in Agilon Health during the fourth quarter valued at approximately $53,000. Finally, Alpine Global Management LLC acquired a new position in Agilon Health during the fourth quarter valued at approximately $84,000.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.